Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 12(64), 2020

DOI: 10.1128/aac.01426-20

Links

Tools

Export citation

Search in Google Scholar

Population Pharmacokinetics of intravenous and oral Acyclovir and oral Valacyclovir in pediatric population to optimize dosing regimens

Journal article published in 2020 by S. Abdalla, C. Briand, M. Oualha ORCID, M. Bendavid, A. Béranger, A. Ranger, S. Benaboud, J. M. Luyer, J.-M. Tréluyer, Yi Zheng, Carmen Capito, Zeynep Demir ORCID, F. Foissac, S. Winter, Inès Gana and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Acyclovir is an antiviral currently used for the prevention and treatment of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. This study aimed to characterize the pharmacokinetics (PK) of acyclovir and its oral prodrug valacyclovir to optimize dosing in children. Children receiving acyclovir or valacyclovir were included in this study. PK were described using nonlinear mixed-effect modeling. Dosing simulations were used to obtain trough concentrations above a 50% inhibitory concentration for HSV or VZV (0.